IGM Biosciences Price Target Raised to 27.00
| IGMS Stock | USD 1.50 0.08 5.06% |
Slightly above 62% of IGM Biosciences' investor base is looking to short. The analysis of overall sentiment of trading IGM Biosciences stock suggests that many investors are alarmed at this time. IGM Biosciences' investing sentiment can be driven by a variety of factors including economic data, IGM Biosciences' earnings reports, geopolitical events, and overall market trends.
IGM |
IGM Biosciences had its price target hoisted by Stifel Nicolaus from 25.00 to 27.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts also recently issued reports about the stock. Guggenheim reduced their price objective on shares of IGM Biosciences
Read at thelincolnianonline.com
 |
IGM Biosciences Fundamental Analysis
We analyze IGM Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
IGM Biosciences is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
IGM Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with IGM Biosciences stock to make a market-neutral strategy. Peer analysis of IGM Biosciences could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics with similar companies.
Peers
IGM Biosciences Related Equities
| RNA | Avidity Biosciences | 1.24 | ||||
| GLUE | Monte Rosa | 0.58 | ||||
| CGEM | Cullinan Oncology | 0.49 | ||||
| STOK | Stoke Therapeutics | 0.31 | ||||
| IKNA | Ikena Oncology | 0.68 | ||||
| RVMD | Revolution Medicines | 1.54 | ||||
| MLYS | Mineralys Therapeutics, | 2.05 | ||||
| PASG | Passage Bio | 3.33 | ||||
| HOWL | Werewolf Therapeutics | 3.55 | ||||
| BDTX | Black Diamond | 7.35 | ||||
| ERAS | Erasca | 8.74 | ||||
| DSGN | Design Therapeutics | 9.05 |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.